2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors

Details for Australian Patent Application No. 2006217744 (hide)

Owner KuDOS Pharmaceuticals Limited

Inventors Hummersone, Marc Geoffrey; Cockcroft, Xiao-Ling Fan; Menear, Keith Allan; Loh, Vincent Junior Ming Lai; Smith, Graeme Cameron Murray; Gomez, Sylvie; Edwards, Peter

Agent Davies Collison Cave

Pub. Number AU-A-2006217744

PCT Pub. Number WO2006/090169

Priority 0503961.5 25.02.05 GB; 60/742,403 05.12.05 US; 60/656,178 25.02.05 US

Filing date 24 February 2006

Wipo publication date 31 August 2006

International Classifications

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

6 September 2007 PCT application entered the National Phase

  PCT publication WO2006/090169 Priority application(s): WO2006/090169

20 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006217752-Method of modifying the viability of a lyophilized microorganism by treating the growth medium thereof with gases

2006217742-Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents